Paul Douglas Godfrin
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2025First federal award
$1.3MFederal grants as PI2 awards
1Patents grantedLatest Oct 6, 2026
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
2 awards · $1.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 11, 2026 | NIH | SBIR Phase II Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer | $935K | VERAMORPH LLC |
| Sep 10, 2025 | NIH | SBIR Phase II Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer | $400K | VERAMORPH LLC |
2 patents as inventor
- US 12751917VERAMORPH LLCOct 6, 2026
- US VERAMORPH LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,499
Awards as PI#1,252
Patents#155
Companies
- VERAMORPH LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.